天津红日药业股份有限公司 2019 年第三季度报告全文 天津红日药业股份有限公司 2019 年第三季度报告 2019-092 2019 年 10 月 1 天津红日药业股份有限公司 2019 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人姚小青、主管会计工作负责人蓝武军及会计机构负责人(会计主 管人员)蓝武军声明：保证季度报告中财务报表的真实、准确、完整。 2 天津红日药业股份有限公司 2019 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |-----------------------------------------------------|------------------|-------------------------|------------------|----- ...

Financial Performance - Total revenue for the reporting period reached CNY 2,287,734,495.95, representing a 16.50% increase compared to CNY 1,963,689,504.00 in the same period last year[35]. - Net profit attributable to shareholders was CNY 350,281,590.72, a slight increase of 1.38% from CNY 345,519,011.70 year-on-year[35]. - Net profit after deducting non-recurring gains and losses was CNY 350,780,584.26, reflecting a 7.82% increase from CNY 325,329,234.96 in the previous year[35]. - The net cash flow from operating activities decreased significantly by 67.55%, amounting to CNY 115,899,756.58 compared to CNY 357,197,563.52 in the same period last year[35]. - Basic earnings per share increased by 2.53% to CNY 0.1177 from CNY 0.1148 in the previous year[35]. - Total assets at the end of the reporting period were CNY 8,108,744,779.91, an increase of 8.35% from CNY 7,483,637,692.87 at the end of the previous year[35]. - Net assets attributable to shareholders rose by 5.19% to CNY 6,737,253,803.43 from CNY 6,405,108,240.33 at the end of the previous year[35]. - The weighted average return on net assets was 5.33%, slightly up from 5.30% in the previous year[35]. - The company reported a non-operating loss of ¥498,993.54, which includes a government subsidy of ¥25,833,594.38 and other non-operating income and expenses[42]. Market and Sales Performance - The sales revenue of finished drugs reached CNY 565.97 million, a slight decrease of 0.03% year-on-year, with a gross margin decline of 1.37 percentage points[53]. - The sales revenue of traditional Chinese medicine formula granules was CNY 1.238 billion, an increase of 25.81% year-on-year, with a gross margin decline of 0.89 percentage points[53]. - The sales revenue of medical devices reached CNY 211.39 million, a significant increase of 82.45% year-on-year[53]. - The company has over 500 types of traditional Chinese medicine formula granules, covering the most frequently used varieties in clinical practice[59]. Research and Development - The company is prioritizing innovation in drug development, with multiple new drugs nearing the critical stage of obtaining production licenses, while also emphasizing the importance of quality control during the R&D process[11]. - The company has 42 ongoing research projects, including 4 Class 1 new drug projects, with 32 varieties submitted for approval and 10 clinical approval projects obtained[68]. - The company has developed a systematic quality control standard system for its traditional Chinese medicine products, exceeding pharmacopoeia standards[63]. - The company has conducted multiple clinical observations and comparative studies, confirming the clinical efficacy of its "Full Component®" formula granules[64]. - The company is actively developing new granule food products aimed at improving throat health, lowering lipids, and enhancing immunity[73]. - The company is focusing on quality control and logistics to capitalize on the opening of local policies in the formula granule industry, which may lead to significant market expansion[125]. Strategic Initiatives - The company is exploring new channels for raw material exports and enhancing product competitiveness through technological cooperation amid uncertainties in overseas markets[12]. - The company is committed to improving the efficiency of its backend operations through the construction of information systems[11]. - The company is responding to the national push for "Internet + healthcare" by promoting the integration of internet services with medical and pharmaceutical sectors[7]. - The company is enhancing its R&D capabilities to accelerate the launch of new products, addressing the high risks associated with drug development[125]. - The company is implementing a multi-channel sales model, combining direct sales, distribution, and agency approaches to boost sales growth[73]. Compliance and Governance - The company is actively monitoring changes in industry policies to mitigate risks and ensure compliance with new regulations[7]. - The company has maintained compliance with all commitments made during the reporting period[134]. - There were no significant litigation or arbitration matters during the reporting period[140]. - The company did not experience any penalties or rectification situations during the reporting period[141]. - The half-year financial report was not audited[138]. Environmental and Social Responsibility - The company has implemented measures to ensure compliance with environmental standards for wastewater, air emissions, noise, and odor[175]. - The company has completed the construction of a 2300t/d wastewater treatment system, which meets regulatory requirements and operates normally[178]. - The company has established emergency response plans for environmental incidents, which have been filed with relevant authorities[178]. Shareholder and Equity Information - The company transferred a total of 487,640,323 shares, accounting for 16.195% of the total share capital, to Xingcheng Group, making it the largest shareholder[180]. - After the share transfer, Xingcheng Group holds 668,303,610 shares, representing 22.195% of the total share capital, and becomes the controlling shareholder[185]. - The company plans to use its own funds to repurchase shares with a total amount not exceeding RMB 200 million, with a maximum price of RMB 5.00 per share[197]. - The company’s major shareholders include Datong Group with 9.74% and Yao Xiaoqing with 13.68% of the total share capital[197].

Financial Performance - Total revenue for Q1 2019 was CNY 1,043,822,547.01, an increase of 8.23% compared to CNY 964,413,376.92 in the same period last year[9]. - Net profit attributable to shareholders was CNY 175,345,606.75, reflecting a growth of 5.13% from CNY 166,782,994.13 year-on-year[9]. - Net profit excluding non-recurring gains and losses was CNY 176,334,060.94, up 7.31% from CNY 164,326,799.82 in the previous year[9]. - The company achieved operating revenue of 1,043.82 million CNY, a year-on-year increase of 8.23%[28]. - The net profit attributable to shareholders reached 175.35 million CNY, reflecting a growth of 5.13% compared to the previous year[28]. - The total profit for the current period was ¥199,236,547.62, slightly up from ¥196,708,887.84 in the last period[86]. - Net profit for the current period was ¥176,319,722.99, representing a 5.93% increase from ¥166,746,610.30 in the previous period[86]. Cash Flow - Net cash flow from operating activities decreased significantly by 76.61%, amounting to CNY 49,828,710.05 compared to CNY 212,994,822.15 in the same quarter last year[9]. - Cash inflow from operating activities totaled CNY 1,177,166,162.77, slightly up from CNY 1,176,802,771.49 year-over-year[100]. - Cash outflow from investing activities reached CNY 190,322,260.72, compared to CNY 56,167,571.79 in the previous year[103]. - Net cash flow from investing activities was negative at CNY -82,448,560.62, worsening from CNY -50,012,862.85 year-over-year[103]. - Cash inflow from financing activities totaled CNY 115,480,000.00, significantly higher than CNY 2,000,000.00 in the previous period[103]. - Net cash flow from financing activities was CNY -52,479,454.18, compared to CNY -853,600.01 in the prior year[103]. - The ending balance of cash and cash equivalents was CNY 1,000,563,738.91, down from CNY 1,380,626,737.11 year-over-year[103]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 7,665,006,713.41, a 2.42% increase from CNY 7,483,637,692.87 at the end of the previous year[9]. - The total liabilities amounted to 919,910,715.30, an increase from 907,608,929.60 in the previous period, reflecting a growth of approximately 0.14%[69]. - The total equity attributable to the parent company reached 6,562,221,358.93, up from 6,405,108,240.33, indicating an increase of about 2.45%[72]. - The total current assets rose to 703,125,335.50 from 607,643,176.10, indicating an increase of approximately 15.7%[76]. - The total liabilities were approximately $907.61 million, with current liabilities accounting for about $836.85 million[113]. Shareholder Information - The top shareholder, Chengdu Xingcheng Investment Group Co., Ltd., holds 16.19% of the shares, with a total of 487,640,323 shares[12]. - The total number of ordinary shareholders at the end of the reporting period was 61,635[12]. - As of the report date, the company has repurchased a total of 34,999,956 shares, accounting for 1.1624% of the total share capital, with a cumulative payment of RMB 117,128,539.50[40]. Investments and Projects - The company has maintained its commitment to avoid competition in the same industry since October 30, 2009[43]. - The company has committed to reducing related party transactions since October 30, 2009[43]. - The total amount of raised funds is 181,926,000 RMB, with 144,435,500 RMB already invested in projects[47]. - The blood purification technology upgrade project has a total investment of 20,190,000 RMB, with 23,939,000 RMB planned, achieving 96.26% completion[47]. - The R&D center construction project has a total investment of 6,601,000 RMB, with 15,949,000 RMB planned, achieving 86.82% completion[47]. - The company plans to enhance its production capacity and R&D capabilities significantly through the ongoing projects[52]. Research and Development - Research and development expenses were ¥27,489,231.03, up from ¥25,044,803.47, indicating a focus on innovation[83]. - The company is actively exploring the development of smart healthcare products while maintaining stable overseas sales in the medical device sector[30]. - The company is focusing on integrating resources to develop a smart medical platform utilizing traditional Chinese medicine big data and intelligent algorithms[36]. - The company is strengthening research and development process control to improve the quality and speed of new product launches[37]. Regulatory and Compliance - The company is enhancing its internal management to address risks from intensified industry regulations and policy changes in the pharmaceutical sector[35]. - The company has not reported any violations regarding external guarantees during the reporting period[56]. - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[59]. - The company has ensured compliance with all commitments made during the reporting period[43].

Financial Performance - The company's revenue for 2018 was approximately ¥4.22 billion, representing a 25.19% increase compared to ¥3.37 billion in 2017[37]. - The net profit attributable to shareholders for 2018 was approximately ¥210.80 million, a decrease of 53.23% from ¥450.73 million in 2017[37]. - The net cash flow from operating activities for 2018 was approximately ¥388.19 million, down 47.71% from ¥742.38 million in 2017[37]. - The basic earnings per share for 2018 was ¥0.07, a decline of 53.33% compared to ¥0.15 in 2017[37]. - The total assets at the end of 2018 were approximately ¥7.48 billion, a slight increase of 0.75% from ¥7.43 billion at the end of 2017[37]. - The net assets attributable to shareholders at the end of 2018 were approximately ¥6.41 billion, an increase of 0.84% from ¥6.35 billion at the end of 2017[37]. - The company reported a quarterly revenue of approximately ¥1.19 billion in Q4 2018, marking a steady growth throughout the year[39]. - The net profit attributable to shareholders in Q4 2018 was a loss of approximately ¥252.44 million, contrasting with profits in the earlier quarters[39]. - The weighted average return on equity for 2018 was 3.29%, down from 7.38% in 2017, indicating a decrease in profitability[37]. - The company achieved operating revenue of 4,223.96 million CNY, a year-on-year increase of 25.19%[74]. - Operating profit was 291.59 million CNY, a year-on-year decrease of 44.49%[74]. - Net profit attributable to shareholders was 210.80 million CNY, a year-on-year decrease of 53.23%[74]. Research and Development - The company plans to enhance its research and development capabilities, with multiple new drugs nearing production approval, while acknowledging the high risks associated with drug development[10]. - The company has developed a comprehensive pharmaceutical health industry cluster, covering modern Chinese medicine, chemical synthesis drugs, biotechnology drugs, and medical services[52]. - The research institute is actively involved in the development of various products, including traditional Chinese medicine injections and small molecule antibody drugs, focusing on critical therapeutic areas such as oncology and neurodegenerative diseases[68]. - Currently, there are 42 ongoing research projects, including 4 new drug projects and 32 submitted varieties, with 10 clinical approval projects and 5 BE registration numbers obtained[69]. - The company emphasizes a multi-level talent development system, ensuring a diverse and skilled workforce to support its research and development efforts[69]. - R&D investment amounted to ¥193,911,245.05 in 2018, accounting for 4.59% of operating revenue[99]. - The number of R&D personnel increased to 686 in 2018, representing 12.50% of the total workforce[99]. Product Development and Market Expansion - The company is focusing on expanding its market presence by developing integrated machines for domestic grassroots healthcare and elderly care markets[11]. - The company is actively expanding its chain model in various regions, including Beijing and Guangdong, enhancing its market presence in traditional Chinese medicine[56]. - The company is focusing on new product development and enhancing automation levels in production to improve capacity[74]. - The company is focusing on the "full-course" Chinese medicine health service model and an integrated platform for the value transformation of Chinese medicine practitioners[77]. - The company aims to build a comprehensive service platform for high-value consumables, enhancing distribution and sales capabilities nationwide[169]. - The company is committed to integrating online and offline healthcare services, leveraging its brand influence to create a strong market presence[166]. Quality Control and Compliance - The quality control system has been significantly enhanced since 2013, achieving national GMP certification and ISO9001 certification, leading to recognition as a national "quality benchmark" in 2017[67]. - The company has established a strict approval system for the use of raised funds to ensure dedicated use[141]. - The company has signed a tripartite supervision agreement for the management of raised funds with relevant financial institutions[141]. - There are no violations in the storage, use, management, and disclosure of raised funds[144]. Financial Management and Dividend Policy - The profit distribution plan approved by the board includes a cash dividend of 0.20 RMB per 10 shares, based on a total of 2,976,054,837 shares[11]. - The total cash dividend, including other methods, amounted to RMB 161,101,018.22, representing 76.43% of the net profit attributable to ordinary shareholders[182]. - The cash dividend payout ratio for 2018 was 28.24% of the net profit attributable to the parent company[182]. - The company achieved a net profit of RMB 210,795,341.94 for the year 2018, with an increase in retained earnings from the previous year[181]. - The company has complied with all commitments made by shareholders and related parties during the reporting period[185]. Challenges and Industry Response - The company is facing challenges from the US-China trade war, which is impacting the pricing competitiveness of its electronic and raw material exports[11]. - The company is actively responding to industry policy changes, including the implementation of cost control measures in healthcare and the promotion of "Internet + Healthcare" initiatives[7]. - The company is committed to improving internal management and adapting to market changes to mitigate risks arising from policy shifts[7]. Subsidiaries and Investments - The company has established production bases in Tianjin, Hebei, Hubei, Gansu, Chongqing, and Henan, with Hebei Hongri Pharmaceutical completing GMP certification[74]. - The company’s subsidiary, Beijing Kangrengtang, produces traditional Chinese medicine formula granules, aiming to capture a larger market share in this segment[52]. - The company’s subsidiary, Tianjin Kangrengtang, completed construction projects leading to a 54.69% increase in fixed assets[59]. - The company’s overseas subsidiary, Hongri International Holdings, reported a net profit of -7.2171 million yuan, accounting for 1.68% of the company's net assets[63].

天津红日药业股份有限公司 2018 年第三季度报告全文 天津红日药业股份有限公司 2018 年第三季度报告 2018-071 2018 年 10 月 1 天津红日药业股份有限公司 2018 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人姚小青、主管会计工作负责人蓝武军及会计机构负责人(会计主 管人员)蓝武军声明：保证季度报告中财务报表的真实、准确、完整。 2 | 项目 | 年初至报告期期末金额 | 说明 | | --- | --- | --- | | 非流动资产处置损益（包括已计提资产减值准备的冲销部分） | -703,909.50 | | | 计入当期损益的政府补助（与企业业务密切相关，按照国家统 一标准定额或定量享受的政府补助除外） | 28,335,364.45 | | | 除上述各项之外的其他营业外收入和支出 | -1,646,055.54 | | | 减：所得税影响额 | 3,890,326.19 | ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of RMB 1.2 billion for the first half of 2018, representing a year-on-year growth of 15%[6] - Total revenue for the reporting period reached ¥1,963,689,504, representing a 36.04% increase compared to ¥1,443,470,341 in the same period last year[21] - Net profit attributable to shareholders was ¥345,519,011.70, up 22.35% from ¥282,403,703.72 year-on-year[21] - Basic earnings per share rose to ¥0.11, reflecting a 22.22% increase from ¥0.09[21] - The company's operating revenue for the reporting period reached CNY 1,963,689,504, representing a year-on-year increase of 36.04% due to higher sales volume[51] - Operating costs increased to CNY 579,885,191, a rise of 33.33%, primarily driven by the increase in sales volume[51] - Sales expenses surged by 54.44% to CNY 758,717,667, correlating with the revenue growth[52] - The net cash flow from operating activities increased by 21.29% to ¥357,197,563.52, compared to ¥294,502,590.03 in the previous year[21] - The company’s cash and cash equivalents increased significantly by 388.23% to CNY 197,978,641, showcasing improved liquidity[52] Market Expansion and Strategy - User data indicates that the company has expanded its customer base by 20%, reaching over 500,000 active users in the healthcare segment[7] - Future outlook includes a projected revenue growth of 10% for the second half of 2018, driven by new product launches and market expansion strategies[6] - The company is focusing on expanding its market presence in rural healthcare, with plans to increase distribution channels by 30% in the next year[7] - The company is actively expanding its market share in traditional Chinese medicine with projects in Hebei and Hubei provinces[29] - The company is expanding its market presence in the international medical device sector, focusing on grassroots and home healthcare markets[46] - The company is increasing investments in the medical services sector, particularly through the expansion of "Yizhen Tang" traditional Chinese medicine management institutions in key cities[121] Research and Development - The company plans to enhance its R&D capabilities, with an investment of RMB 200 million allocated for new drug development and innovation in the next fiscal year[6] - The research institute has 42 ongoing projects, including 4 Class 1 new drug projects and 28 submitted varieties, with 10 clinical approval projects obtained[41] - The company has established a collaborative innovation platform for tumor immunotherapy with the Chinese Academy of Medical Sciences, promoting a new model for drug innovation[41] - The company is focusing on modernizing traditional Chinese medicine production processes, utilizing advanced technologies to ensure product quality and safety[37] - The company is conducting a multi-center clinical study for the blood-purifying injection, with over 40 centers involved and nearly 1,000 participants enrolled[44] Financial Position and Investments - Total assets at the end of the reporting period were ¥7,778,897,663.33, a 4.72% increase from ¥7,428,215,418.85 at the end of the previous year[21] - The company’s fixed assets increased by 42.93% compared to the beginning of the period, primarily due to the completion of a project by its subsidiary Tianjin Kangrengtang[34] - The company’s equity assets grew by 84.95% compared to the beginning of the period, mainly due to increased investment income from its associate Tianyi Fund[34] - The company has not declared any cash dividends for the current fiscal year, opting to reinvest profits into business growth initiatives[8] - The company reported a guarantee amount of 950 million yuan for Hubei Wurui Biotechnology Co., Ltd., with a guarantee period of 36 months[108] Challenges and Risks - The company is facing challenges due to currency fluctuations, which have impacted the pricing competitiveness of its export business[7] - The company is facing challenges in drug development due to high investment and long cycles, necessitating improved process control and quality assurance[84] - The company is preparing for potential policy changes in the herbal medicine sector, positioning itself to capitalize on market opportunities as regulations evolve[6] Corporate Governance and Compliance - The company has not reported any overdue bonds or debts as of the report date, indicating a stable financial position[147] - The half-year financial report was not audited[92] - The company maintained compliance with all commitments made to shareholders during the reporting period[91] - There were no significant litigation or arbitration matters during the reporting period[94] - The company did not have any major related party transactions during the reporting period[98] Environmental and Social Responsibility - The company has established a comprehensive emergency response plan for environmental incidents, which has been filed with relevant authorities[117] - The company has implemented a nitrogen oxide discharge of 0.2724 tons, with an annual limit of 5.31 tons, and no exceedance of discharge standards[115] - The company has a wastewater treatment system with a capacity of 1000 tons per day, which meets regulatory requirements and operates normally[117] - The company reported no ongoing or planned poverty alleviation initiatives as of the half-year report[119]

天津红日药业股份有限公司 2018 年第一季度报告全文 天津红日药业股份有限公司 2018 年第一季度报告 2018-022 2018 年 04 月 1 天津红日药业股份有限公司 2018 年第一季度报告全文 第一节 重要提示 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业总收入（元） | 964,413,376.92 | 732,944,389.26 | 31.58% | | 归属于上市公司股东的净利润（元） | 166,782,994.13 | 132,549,458.48 | 25.83% | | 归属于上市公司股东的扣除非经常性损 益的净利润（元） | 164,326,799.82 | 125,807,981.55 | 30.62% | | 经营活动产生的现金流量净额（元） | 212,994,822.15 | 90,383,821.16 | 135.66% | | 基本每股收益（元/股） | 0.06 | 0.04 | 50.00% | | 稀释每股收益（元/股） ...

天津红日药业股份有限公司 2017 年年度报告全文 天津红日药业股份有限公司 2017 年年度报告 2018-017 2018 年 03 月 1 天津红日药业股份有限公司 2017 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人姚小青、主管会计工作负责人蓝武军及会计机构负责人(会计主 管人员)蓝武军声明：保证年度报告中财务报告的真实、准确、完整。 本公司请投资者认真阅读本年度报告全文，并特别注意下列风险因素： 1、基层首诊、双向转诊、远程问诊等医改举措，已经从政策设计阶段，进 入具体实施阶段，部分省市规定了基层首诊的病种，且规定了越级首诊的医保 报销下浮比例。基层首诊等政策落地和不断成熟会改变患者就医习惯，城市等 级医院增速可能放缓，第三终端等市场规模快速扩大。 就医方式的结构性变化， 将对医药企业的能力建设方式产生影响。公司在基层医疗机构管理、医患互动、 第三终端医技提升等方面进行了软硬件产品准备。 2、配方颗粒行业政策放开的可能性不断加大，工艺、 ...

天津红日药业股份有限公司 2017 年第三季度报告全文 1 天津红日药业股份有限公司 2017 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人姚小青、主管会计工作负责人蓝武军及会计机构负责人(会计主 管人员)蓝武军声明：保证季度报告中财务报表的真实、准确、完整。 天津红日药业股份有限公司 2017 年第三季度报告 2017-058 2017 年 10 月 2 天津红日药业股份有限公司 2017 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 7,386,955,095.88 | 7,281,311,089.45 | | 1.45% | | 归属于上市公司股东的净资产 | 6,3 ...

天津红日药业股份有限公司 2017 年半年度报告全文 天津红日药业股份有限公司 2017 年半年度报告 2017-049 2017 年 08 月 0 天津红日药业股份有限公司 2017 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人姚小青、主管会计工作负责人蓝武军及会计机构负责人(会计主 管人员)蓝武军声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本公司请投资者认真阅读本半年度报告全文，并特别注意下列风险因素： 1、基层首诊、双向转诊、远程问诊等医改举措，已经从政策设计阶段，进 入具体实施阶段。部分省市规定了基层首诊的病种，且规定了越级首诊的医保 报销下浮比例。基层首诊政策的落地，不仅会影响规定病种就医习惯，在基层 首诊和转诊体系发展成熟后，几乎所有常见疾病领域患者的就医习惯都会改变。 就医方式的结构性变化，将对医药公司的能力建设方式产生影响。公司在基层 医疗机构管理、医患互动、第三终端医技提 ...